Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Chaperone protein DnaK is the primary bacterial representative of the Hsp70 family, serving as a central hub in the protein folding machinery (UniProt P0A6Y8). It facilitates the folding of newly synthesized proteins, prevents the aggregation of misfolded proteins, and assists in the translocation of proteins across membranes (PMID: 28836138). The functional cycle of DnaK is tightly regulated by its co-chaperones, DnaJ and GrpE, which modulate its ATP-bound and ADP-bound states to control substrate affinity (PMID: 31434151). In the context of infection, DnaK is crucial for bacterial survival under the stressful conditions of the host environment, such as high temperature and oxidative stress, and is often linked to the expression of virulence factors (PMID: 25613164). As a therapeutic target, DnaK is inhibited by various proline-rich antimicrobial peptides (PrAMPs) like apidaecin and oncocin, which bind to its substrate-binding pocket and stall the chaperone cycle (PMID: 21664394). This inhibition leads to the accumulation of misfolded proteins and eventual bacterial cell death, making it a high-priority target for addressing multi-drug resistant bacterial pathogens (PMID: 17506534).
Inhibition of the chaperone cycle by binding to the substrate-binding domain, preventing protein refolding and causing lethal protein aggregation (PMID: 21664394, 31434151).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Chaperone protein DnaK (DnaK).